Fourth anniversary issue; The Buyside View, V

For the middle-aged among us still able to remember the days of Catskill humor, the comedian Alan Sherman wrote a set of lyrics that could epitomize the experience of biotech investors in 1996 and their hopes for 1997:

"God rest ye merry gentlemen, let nothing you dismay, Dis May you had a rotten month, so what is there to say, Let's hope next May is better and good things will come your way, And you won't have a feeling of dismay, next May."Biotech investors are, of necessity, optimists. The sector was flat for 1996, yet by any measure, the group made fundamental progress last year, with more companies making money, more products approved, more awaiting approval, and more advancing through clinical trials. For its fifth annual review of investor sentiment for the new year, BioCentury asked institutional investors when, and how, that will be reflected in stock prices.

The problem for biotech is that it exists in a broader environment, where investors have multiple options of where to put their money. Thus 1996 was a year of contradictions for the industry

For the middle-aged among us still able to remember the days of Catskill humor, the comedian Alan Sherman wrote a set of lyrics that could epitomize the experience of biotech investors in 1996 and their hopes for 1997:

"God rest ye merry gentlemen, let nothing you dismay,

Dis May you had a rotten month, so what is there to say,

Let's hope next May is better and good things will come your way,

And you won't have a feeling of dismay, next May."

Biotech investors are, of necessity, optimists. The sector was flat for 1996, yet by any measure, the group made fundamental progress last year, with more companies making money, more products approved, more awaiting approval, and more advancing through clinical trials. For its fifth annual review of investor sentiment for the new year, BioCentury asked institutional investors when, and how, that will be reflected in stock prices.

The problem for biotech is that it exists in a broader environment, where investors have multiple options of where to put their money. Thus 1996 was a year of contradictions for the industry

A letdown

A letdown

As described by Sandra Panem, who manages Vector's Later-Stage Equity Fund, "if you look at the number of products in late-stage clinical development, and at the increasing number of companies becoming self-sufficient, it says there's extraordinary success. But if you bought biotech at the beginning of the year, you might not be as happy as if you bought the S&P." The BioCentury 100 price index was off 8 percent on the year; by comparison, the S&P 500 gained 20 percent.

The gap in valuations runs both ways, according to Mark

Read the full 4500 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE